Evidence map›Paper›PMID 41599769›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3.

Lukas Greifenstein, Marcel Martin, Sarah Stephan, Aleksandr Eismant, Carsten S Kramer, Christian Landvogt, Corinna Mueller, Frank Rösch, Richard P Baum

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lukas GreifensteinCURANOSTICUM MVZ GmbH Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.ORCID 0000-0003-4040-8468
Marcel MartinDepartment of Chemistry-TRIGA, Institute of Nuclear Chemistry, Johannes Gutenberg University, 55122 Mainz, Germany.
Sarah StephanCURANOSTICUM MVZ GmbH Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Aleksandr EismantCURANOSTICUM MVZ GmbH Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Carsten S KramerCURANOSTICUM MVZ GmbH Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Christian LandvogtCURANOSTICUM MVZ GmbH Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Corinna MuellerCURANOSTICUM MVZ GmbH Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
Frank RöschDepartment of Chemistry-TRIGA, Institute of Nuclear Chemistry, Johannes Gutenberg University, 55122 Mainz, Germany.
Richard P BaumCURANOSTICUM MVZ GmbH Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Actinium-225 (Ac-225)DOTA-LM3molecular imagingneuroendocrine tumors (NETs)peptide receptor radionuclide therapy (PRRT)radionuclide therapyradiopharmaceuticalssomatostatin receptor 2 (SSTR2) antagonisttargeted alpha therapy (TAT)theranostics

Identifiers

PMID41599769
PMCPMC12845222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.